Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode (TM) Whole ...
Morningstar

Parse Biosciences and Codebreaker Labs Partner to Apply Whole Transcriptome Single Cell Profiling and Causal Genomics at Scale

Collaboration pairs robust synthetic biology platform with massive scale single cell sequencing to overcome long-standing challenges in variant mapping Parse Biosciences, the leading provider of ...
Morningstar

Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery

New chemistry reduces barriers to scaling single-cell studies across research settings Launch planned for March 2026, available across Evercode Whole Transcriptome product line Parse Biosciences, a ...
Frontiers

Deciphering the immune microenvironment of rare cancers

Rare cancers encompass a heterogeneous group of malignancies characterized by low incidence and prevalence but, often, disproportionately high mortality ...